Article
A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis demonstrates both the benefits and harms to early glucocorticoid regimens on lupus outcomes.
All News
Article
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
Article
A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis patients with chronic kidney disease, shows the 3 year survival to be under 50% but that all studied biologics were nearly equivalents with regard to safety and efficacy.
Article
A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.
Article
A UK cross-sectional EHR clinical practice analysis between 2004 and 2020 shows that analgesic prescribing in inflammatory arthritis patients has declined, but still remains substantial, including opioid prescribing. Data was drawn from the Clinical Practice Research Datalink Aurum to evaluate analgesic prescription annual prevalence in patients with RA, PsA and axSpA and found that analgesic prescribing declined over time but remained common.
Dr. John Cush
Tweet
FDA has approved Eli Lilly’s GLP-1 drug Zepbound [tirzepatide] to treat moderate to severe obstructive sleep apnea in adults with obesity in combination with increased physical activity and a reduced-calorie diet.” https://t.co/rYiM6JzmDX https://t.co/hO6CgH9pVs
Dr. John Cush
Tweet
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w76dY29bwe https://t.co/1LBevDunjH https://t.co/Ix3UxeGUe2
Dr. John Cush
Tweet
"If you want an argument, put two rheumatologists in a room and ask them about steroid tapers. Add a third and you'll have a fight"
-P. Merkel at UPA plenary session
#ACR24 @RheumNow
Dr. John Cush
Tweet
Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/f7OwxAggaf… https://t.co/PUuwo0MLso https://t.co/JBzokT9icx
Dr. John Cush
Tweet
Should you worry about giving TNFi to RA pts after a cancer diagnosis?
Medicare data with colorectal, lung, prostate Ca:
TNFi pts survival no worse (numerically better) than csDMARDs
Cancer pts deserve good RA treatment!
#ACR24 ABST0202 Suarez-Almazor @MDAndersonNews @RheumNow… https://t.co/aR75hJQ6YK https://t.co/ptDYCsOpXN
Dr. John Cush
Tweet
ANA neg, but ENA pos
should we care about that result?
PPV 5.5% here
(similar to 6% prev @EricFMorand: https://t.co/7Lo0DgHtXT)
and how many really needed the serology? Anxiety?
Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️
#ACR24 ABST1930 @RheumNow… https://t.co/lZ1TJxTqhs https://t.co/itx0TCFFjl
Dr. John Cush
Tweet
Great table re:side effects of even low dose steroids in RA
Likely generalizes to other diseases ie PMR, SLE
P in prednisone stands for poison!
#ACR24 @RheumNow https://t.co/2bFy6dwl96 https://t.co/YDtjSX054I
Dr. John Cush
Tweet
TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/F9DOBLrjVq https://t.co/BtphAuEopA
Dr. John Cush
Tweet
54K Peptic Ulcers Annually (12.13.2024)
https://t.co/18FiQx1YQA https://t.co/32UZi9XafS
Dr. John Cush
Tweet
#ACR24 Year in Review:
💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨)
💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?)
💡 High risk of CV events within 30 days of gout… https://t.co/g3egOpCYNr https://t.co/KMiOEP7pSg
Dr. John Cush
Tweet
RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease:
➡️ A. Ogdie: Preventing PsA
➡️ A. Kavanaugh: Biologic Therapies
➡️ K. Gordon: Head-to-Head Studies
Register now!
https://t.co/9qnqtpkwpT https://t.co/95TGS56vyA
Dr. John Cush
Tweet
Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes
A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated.
https://t.co/8wvSy8555Z https://t.co/vaGt1AylBr
Dr. John Cush
Tweet
Metanalysis of 41 studies, & 5343 AAV pts showed 55% (2890) had infection; 36% w/ severe infxn. This included PJP, aspergillosis, candidiasis, HZ, CMV, etc. Pulmonary most common. Risk factors included older, ESRD, DM, smoking, Renal or lung involvement https://t.co/yHo5BNlbiL https://t.co/R2je32YYGy
Dr. John Cush
Tweet
Best of 2024: Prescription Painkiller Misuse in Chronic Pain Patients
https://t.co/AyccRCuAHh https://t.co/RYuvDwHANo
Dr. John Cush
Tweet
Abuse of the Safety-Net 340B Drug Programs
Dr. Madelaine Feldman comments on the 340B Drug Pricing Program, a safety-net initiative designed to provide costly therapies to vulnerable populations. She argues that the program has deviated from its original intent, with certain… https://t.co/5rIQHsIeAS https://t.co/rXwQPctHDf
